Breast cancer management: Past, present and evolving

Indian Journal of Cancer

Volumn 49, Issue 3, 2012, Pages 277-282

  Akram, M ^a   Siddiqui, S A ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Biological agents; carcinoma breast; evolution; hormone therapy; management

Indexed keywords

AFATINIB; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GONADORELIN AGONIST; IMATINIB; IXABEPILONE; LAPATINIB; LETROZOLE; MELPHALAN; METHOTREXATE; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PERTUZUMAB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VINBLASTINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; BRACHYTHERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENDOCRINE SURGERY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTRAOPERATIVE RADIOTHERAPY; LYMPH NODE DISSECTION; MASTECTOMY; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT PREFERENCE; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; SURGICAL APPROACH; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HISTORY, MEDIEVAL; HUMANS; INDIVIDUALIZED MEDICINE; MASTECTOMY, RADICAL; MOLECULAR TARGETED THERAPY; RADIOTHERAPY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84871631468     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.104486     Document Type: Conference Paper

References (44)

1. Hellman S. Dogma and Inquisition in Medicine. Cancer 1993; 71: 2430-3.
2. Halsted WS. The Results of Radical Operations for the Cure of Carcinoma of the Breast. Ann Surg 1907; 46:1-19.
3. Murphy JB. Carcinoma of Breast. Surgical Clinics of J B Murphy 1912; 6:779.
4. Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer 1948; 2:7-13.
5. Rosner D, Bedwani RN, Vana J, Baker HW, Murphy GP. Noninvasive Breast Carcinoma: Results of a National Survey by the American College of Surgeons. Ann Surg 1980; 192:139-47.
6. Wilson RE, Donegan WL, Mettlin C, Natarajan N, Smart CR, Murphy GP. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet 1984; 159:309-18.
7. McWhirter R. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Br J Radiol 1948; 21:599-10.
8. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, et al. Ten-year results of a randomized clinical trial comparing the radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312:674-81.
9. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320:822-8.
10. Pfahler GE. Results of radiation therapy in 1022 private cases of carcinoma of the breast from 1902 to 1928. Am J Roentgenol Rad Ther 1932; 27:497-08.
11. Keynes G. The Place of Radium in the treatment of cancer of the breast. Ann Surg 1937; 106:619-30.
12. Baclesse F. Roentgen therapy as the sole method of treatment of cancer of the breast. Am J Roentgenol 1949; 62:311.
13. Atkins H, Hayward JL, Klugman DJ, Wayte AB. Treatment for early breast cancer: A report after ten years of a clinical trial. Br Med J 1972; 2:423-9.
14. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med 1997; 337:949-55.
15. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med 1997; 337:956-62.
16. Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol 1999; 9:292-9.
17. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2:104-7.
18. Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res1952; 12:134-41.
19. Luft R, Olivecrona H. Hypophysectomy in man: experiences in metastatic cancer of the breast. Cancer 1955; 8:261-70.
20. Dawood S, Kristine B, Hortobagyl GN, Glordano S. Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: an institutional based review. J Clin Oncol 2008; 26:1018.
21. Croxtall JD. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 2011; 71:363-80.
22. Marchall EK Jr. Historical perspectives in chemotherapy. Adv Chemother 1964; 13:1-8.
23. De Lena M, Brambilla C, Morabito A, Bonadonna G. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-Fluorouracil for advanced breast cancer. Cancer 1975; 35:1108-15.
24. Brambilla C, De Lena M, Rossi A, Valgussa P, Bonadonna G. Response and survival in advanced breast cancer after two noncross-resistant combinations. Br Med J 1976; 1:801-04.
25. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294:405-10.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
27. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23:3686-96.
28. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-13.
29. Slamon, DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
31. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
32. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-43.
33. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66:1630-9.
34. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 9:10-5.
35. Drew Y, Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 2008; 1138:136-45.
36. Muñoz-Gámez JA, Martín-Oliva D, Aguilar-Quesada R, Cañuelo A, Nuñez MI, Valenzuela MT, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005; 386:119-25.
37. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple negative phenotype. A population based study from the California Cancer Registry. Cancer 2007; 109:1721-8.
38. Roch́e H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25:3415-20.
39. Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25:3399-406.
40. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycine and taxane treatment. J Clin Oncol 2007; 25:5210-7.
41. Cardoso F, Castiglione M. ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20:15-8.
42. Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentanich CRM. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342:525-33.
43. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumour cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13:920-8.
44. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 2008; 196:527-9.